Last reviewed · How we verify
NCT04571112: 2T-DBS
GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment
NA trial testing NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US) in Parkinson Disease in 6 participants. Completed in 1 March 2021.
1 October 2020
Quick facts
| Lead sponsor | University of Toronto |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 4 December 2017 |
| Primary completion | 1 October 2020 |
| Estimated completion | 1 March 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- NBM stimulation using the Vercise device (Boston Scientific, Marlborough, Massachusetts, US)
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
- Memory Disorders — all drugs for Memory Disorders →
Sponsor
University of Toronto
Who can join
Eligibility, any sex, with Parkinson Disease or Memory Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study examines the safety and feasibility of DBS in treating the movement and cognitive dysfunction in Parkinson's disease (PD). Globus pallidus interna (GPi) stimulation is an established treatment for the motor symptoms in PD, but it does not treat the cognitive symptoms that can also be seen in this condition. It is theorized that we can improve cognitive dysfunction by stimulating a part of the brain called the nucleus basalis of Meynert (NBM), which releases a chemical (acetylcholine) and plays a role in memory and attention. By using a novel DBS system (Vercise device) with 2 electrodes that are designed to stimulate the GPi and NBM, we can potentially target the motor and cognitive symptoms of PD with a single intervention.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions.
Sun C, Armstrong MJ. · · 2021 · cited 50× · PMID 33920698 · DOI 10.3390/bs11040054 -
Electrical stimulation of the nucleus basalis of meynert: a systematic review of preclinical and clinical data.
Nazmuddin M, Philippens IHCHM, van Laar T. · · 2021 · cited 25× · PMID 34083732 · DOI 10.1038/s41598-021-91391-0
Verify or expand the search:
- PubMed search for NCT04571112
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other University of Toronto trials
Trials by the same sponsor.
- NCT07184255 — Animated Video Education for Retinal Surgery · NA · not yet recruiting
- NCT07259434 — Time Restricted Eating in Survivors Trial 2.0 · NA · not yet recruiting
- NCT07486050 — The Impact of Social Worker Referrals on Diabetes and Loneliness · NA · active not recruiting
- NCT07268729 — Investigation of Pathogenic Gut Microbiota Patterns in Anxiety, Depression and Panic Disorders · not yet recruiting
- NCT07317921 — Validating IAAO for Muscle Outcomes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04571112 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Toronto
- Last refreshed: 2 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04571112.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing